Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy – a narrative review

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Lesokhin AM, Ansell SM, Armand P et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J. Clin. Oncol. 34(23), 2698–2704 (2016).
  Medline CASGoogle Scholar
• 2. Younes A, Santoro A, Shipp M et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 17(9), 1283–1294 (2016).
  Medline CASGoogle Scholar
• 3. Chen R, Zinzani PL, Lee HJ et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134(14), 1144–1153 (2019).
  Medline CASGoogle Scholar
• 4. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
  Medline CASGoogle Scholar
• 5. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006–2017 (2015).
  MedlineGoogle Scholar
• 6. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
  Medline CASGoogle Scholar
• 7. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32(10), 1020–1030 (2014).
  Medline CASGoogle Scholar
• 8. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer. JACC CardioOncol. 3(1), 35–47 (2021). •• This is probably the most important paper and bigger casuistry concerning immune checkpoint inhibitor (ICI)-myocarditis.
  MedlineGoogle Scholar
• 9. Waliany S, Lee D, Witteles RM et al. Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. Annu. Rev. Pharmacol. Toxicol. 61, 113–134 (2021). • This was one of the most important papers that guided our comprehension of the mechanism underlying ICI-related cardiotoxicity.
  Medline CASGoogle Scholar
• 10. Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375(18), 1749–1755 (2016).
  MedlineGoogle Scholar
• 11. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur. J. Heart Fail. 23(10), 1739–1747 (2021). • This well-written metanalysis gave us and the scientific community an accurate photograph of epidemiology concerning this adverse event.
  Medline CASGoogle Scholar
• 12. Wei SC, Meijers WC, Axelrod ML et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 11(3), 614–625 (2021).
  Medline CASGoogle Scholar
• 13. Hu JR, Florido R, Lipson EJ et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc. Res. 115(5), 854–868 (2019).
  Medline CASGoogle Scholar
• 14. Pirozzi F, Poto R, Aran L et al. Cardiovascular toxicity of immune checkpoint inhibitors: clinical risk factors. Curr. Oncol. Rep. 23(2), 13 (2021).
  MedlineGoogle Scholar
• 15. Lal JC, Brown SA, Collier P, Cheng F. A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. Cardiooncology 7(1), 19 (2021).
  MedlineGoogle Scholar
• 16. Thangavelu G, Smolarchuk C, Anderson CC. Co-inhibitory molecules: controlling the effectors or controlling the controllers? Self/Nonself 1(2), 77–88 (2010).
  MedlineGoogle Scholar
• 17. Patel RP, Parikh R, Gunturu KS et al. Cardiotoxicity of immune checkpoint inhibitors. Curr. Oncol. Rep. 23(7), 79 (2021).
  MedlineGoogle Scholar
• 19. Mahmood SS, Fradley MG, Cohen JV et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71(16), 1755–1764 (2018).
  Medline CASGoogle Scholar
• 20. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124), 933 (2018).
  MedlineGoogle Scholar
• 21. Salem JE, Manouchehri A, Moey M et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19(12), 1579–1589 (2018). •• This pharmacovigilance study helped a deeper comprehension on this fascinating field paving the way to a risk stratification process for patients undergoing to ICI therapy.
  Medline CASGoogle Scholar
• 22. Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet 392(10145), 382–383 (2018).
  MedlineGoogle Scholar
• 23. Escudier M, Cautela J, Malissen N et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136(21), 2085–2087 (2017).
  MedlineGoogle Scholar
• 24. Shalata W, Abu-Salman A, Steckbeck R, Jacob BM, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers (Basel) 13(20), 5218 (2021).
  Medline CASGoogle Scholar
• 25. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124), 933 (2018).
  MedlineGoogle Scholar
• 26. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood 131(1), 58–67 (2018).
  Medline CASGoogle Scholar
• 27. Qin W, Hu L, Zhang X et al. The diverse function of PD-1/PD-L pathway beyond cancer. Front. Immunol. 10, 2298 (2019).
  Medline CASGoogle Scholar
• 28. Baik AH, Oluwole OO, Johnson DB et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ. Res. 128(11), 1780–1801 (2021).
  Medline CASGoogle Scholar
• 29. Tay WT, Fang YH, Beh ST et al. Programmed cell death-1: programmed cell death - ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro. Int. J. Mol. Sci. 21(7), 2399 (2020).
  Medline CASGoogle Scholar
• 30. Ammirati E, Frigerio M, Adler ED et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ. Heart Fail. 13(11), e007405 (2020).
  MedlineGoogle Scholar
• 31. Palaskas NL, Segura A, Lelenwa L et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur. J. Heart Fail. 23(10), 1725–1735 (2021).
  Medline CASGoogle Scholar
• 32. Wang J, Okazaki IM, Yoshida T et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol. 22(6), 443–452 (2010).
  Medline CASGoogle Scholar
• 33. Xu S, Sharma UC, Tuttle C, Pokharel S. Immune checkpoint inhibitors: cardiotoxicity in pre-clinical models and clinical studies. Front. Cardiovasc. Med. 8, 619650 (2021).
  Medline CASGoogle Scholar
• 34. Brahmer JR, Lacchetti C, Schneider BJ et al. National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36(17), 1714–1768 (2018).
  Medline CASGoogle Scholar
• 35. Tadokoro T, Keshino E, Makiyama A et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ. Heart Fail. 9(10), e003514 (2016).
  MedlineGoogle Scholar
• 36. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer 21, 3–11 (2015).
  Google Scholar
• 37. Amiri-Kordestani L, Moslehi J, Cheng J et al. Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a US Food and Drug Administration pooled analysis. J. Clin. Oncol. 9(2), e013757 (2018).
  Google Scholar
• 38. Lyon AR, López-Fernández T, Couch LS et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. 43(41), 4229–4361 (2022).
  MedlineGoogle Scholar
• 39. Chuy KL, Oikonomou EK, Postow MA et al. Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the Memorial Sloan Kettering Cancer Center experience. Oncologist 24(5), e196–e197 (2019). • Despite the suggested surveillance protocol's failed in demonstrating to improve early myocarditis detection, the authors underlined that identification of reliable predictors in this setting remains fundamental.
  MedlineGoogle Scholar
• 40. Waliany S, Neal JW, Reddy S et al. Myocarditis surveillance with high-sensitivity Troponin I during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol. 23(1), 137–139 (2021).
  Google Scholar
• 41. Song W, Zheng Y, Dong M et al. Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis. Curr. Probl. Cardiol. 48(2), 101478 (2023).
  MedlineGoogle Scholar
• 42. Pradhan R, Nautiyal A, Singh S. Diagnosis of immune checkpoint inhibitor-associated myocarditis: a systematic review. Int. J. Cardiol. 296, 113–121 (2019).
  MedlineGoogle Scholar
• 43. Awadalla M, Mahmood SS, Groarke JD et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J. Am. Coll. Cardiol. 75(5), 467–478 (2020).
  Medline CASGoogle Scholar
• 44. Friedrich MG, Sechtem U, Schulz-Menger J et al. International consensus group on cardiovascular magnetic resonance in myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J. Am. Coll. Cardiol. 53(17), 1475–1487 (2009).
  MedlineGoogle Scholar
• 45. Blissett S, Chocron Y, Kovacina B, Afilalo J. Diagnostic and prognostic value of cardiac magnetic resonance in acute myocarditis: a systematic review and meta-analysis. Int. J. Cardiovasc. Imaging 35, 2221–2229 (2019).
  MedlineGoogle Scholar
• 46. Ferreira VM, Schulz-Menger J, Holmvang G et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J. Am. Coll. Cardiol. 72(24), 3158–3176 (2018).
  MedlineGoogle Scholar
• 47. Thavendiranathan P, Zhang L, Zafar A et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis. J. Am. Coll. Cardiol. 77(12), 1503–1516 (2021).
  MedlineGoogle Scholar
• 48. Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am. J. Cardiol. 111(5), 717–722 (2013).
  Medline CASGoogle Scholar
• 49. Pavan A, Attili I, Pasello G, Guarneri V, Conte PF, Bonanno L. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. J. Immunother. Cancer 7(1), 205 (2019).
  Medline CASGoogle Scholar
• 50. Caforio ALP, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur. Heart J. 34(33), 2636–2648 (2013).
  MedlineGoogle Scholar
• 51. Ammirati E, Buono A, Moroni F et al. State-of-the-art of endomyocardial biopsy on acute myocarditis and chronic inflammatory cardiomyopathy. Curr. Cardiol. Rep. 24(5), 597–609 (2022).
  MedlineGoogle Scholar
• 52. Sobol I, Chen CL, Mahmood SS, Borczuk AC. Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy. Arch. Pathol. Lab. Med. 144(11), 1392–1396 (2020).
  Medline CASGoogle Scholar
• 53. Allenbach Y, Anquetil C, Manouchehri A et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun. Rev. 19(8), 102586 (2020).
  Medline CASGoogle Scholar
• 54. Samara Y, Yu CL, Dasanu CA. Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. J. Oncol. Pharm. Pract. 25(4), 966–968 (2019).
  MedlineGoogle Scholar
• 55. Zhang L, Zlotoff DA, Awadalla M et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 141(24), 2031–2034 (2020).
  Medline CASGoogle Scholar
• 56. Wang C, Lin J, Wang Y et al. Case series of steroid-resistant immune-checkpoint inhibitor associated myocarditis: a comparative analysis of corticosteroid and tofacitinib treatment. Front. Pharmacol. 12, 770631 (2021).
  Medline CASGoogle Scholar
• 57. Nguyen LS, Bretagne M, Arrondeau J et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J. Immunother. Cancer 10, e004699 (2022).
  MedlineGoogle Scholar
• 58. Arangalage D, Delyon J, Lermuzeaux M et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann. Intern. Med. 167(9), 683–684 (2017).
  MedlineGoogle Scholar
• 59. Tay RY, Blackley E, McLean C et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br. J. Cancer 117(7), 921–924 (2017).
  Medline CASGoogle Scholar
• 60. Kociol RD, Cooper LT, Fang JC et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation 141(6), e69–e92 (2020).
  MedlineGoogle Scholar
• 61. Frigeri M, Meyer P, Banfi C et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can. J. Cardiol. 34(1), 92.e1–92.e3 (2018).
  MedlineGoogle Scholar
• 62. Salem JE, Allenbach Y, Vozy A et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N. Engl. J. Med. 380(24), 2377–2379 (2019).
  MedlineGoogle Scholar
• 63. Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N. Engl. J. Med. 380(24), 2375–2376 (2019).
  MedlineGoogle Scholar
• 64. Geraud A, Gougis P, Vozy A et al. Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance. Annu. Rev. Pharmacol. Toxicol. 61, 85–112 (2021).
  Medline CASGoogle Scholar
• 65. Doms J, Prior JO, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann. Oncol. 31(9), 1273–1275 (2020).
  Medline CASGoogle Scholar
• 66. Petrelli F, Signorelli D, Ghidini M et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 12(3), 546 (2020).
  Medline CASGoogle Scholar
• 67. McDonagh TA, Metra M, Adamo M et al. ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 42(36), 3599–3726 (2021).
  Medline CASGoogle Scholar
• 68. ESC Scientific Document Group, Zeppenfeld K, Tfelt-Hansen J, de Riva M et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 43(40), 3997–4126 (2022).
  MedlineGoogle Scholar
• 69. Salem JE, Bretagne M, Abbar B et al. Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. doi: 10.1158/2159-8290.CD-22-1180 (2023).
  MedlineGoogle Scholar
• 70. Dolladille C, Ederhy S, Sassier M et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 6(6), 865–871 (2020).
  MedlineGoogle Scholar
• 71. Vasbinder A, Chen Y, Procureur A et al. Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC CardioOncol. 4(5), 689–700 (2022).
  MedlineGoogle Scholar
• 72. Boughdad S, Latifyan S, Fenwick C et al. ⁶⁸Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. J. Immunother. Cancer 9(10), e003594 (2021).
  MedlineGoogle Scholar
• 73. Aldrich J, Pundole X, Tummala S et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol. 73, 866–874 (2021).
  Medline CASGoogle Scholar
• 74. Lehmann LH, Cautela J, Palaskas N et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 6, 1329–1337 (2021).
  MedlineGoogle Scholar